Evidence map›Paper›PMID 40502919›Full record

ArticleMolecular therapy. Oncology2025

Enhancing plasmacytoid dendritic cell functionality with

Wanli Yu, Wenting Tang, Wei Lin, Ling Jiang, Yuyang Xiang, Yinyin Li, Yang Zhou, Yuyang Chen, Wenli Zhao, Yihan Zhu and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Wanli YuDepartment of Biochemistry and Molecular Biology, School of Basic Medical, Southern Medical University, Guangzhou 510515, China.
Wenting TangDivision of Nephrology, Nanfang Hospital, Southern Medical University, State Key Laboratory of Multi-organ Injury Prevention and Treatment, National Clinical Research Center for Kidney Disease, Guangdong Provincial Institute of Nephrology, Guangdong Provincial Key Laboratory of Renal Failure Research, Guangzhou, Guangdong 510515, China.
Wei LinDepartment of Biochemistry and Molecular Biology, School of Basic Medical, Southern Medical University, Guangzhou 510515, China.
Ling JiangDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Yuyang XiangDepartment of Biochemistry and Molecular Biology, School of Basic Medical, Southern Medical University, Guangzhou 510515, China.
Yinyin LiDivision of Nephrology, Nanfang Hospital, Southern Medical University, State Key Laboratory of Multi-organ Injury Prevention and Treatment, National Clinical Research Center for Kidney Disease, Guangdong Provincial Institute of Nephrology, Guangdong Provincial Key Laboratory of Renal Failure Research, Guangzhou, Guangdong 510515, China.
Yang ZhouDepartment of Biochemistry and Molecular Biology, School of Basic Medical, Southern Medical University, Guangzhou 510515, China.
Yuyang ChenDepartment of Biochemistry and Molecular Biology, School of Basic Medical, Southern Medical University, Guangzhou 510515, China.
Wenli ZhaoDepartment of Biochemistry and Molecular Biology, School of Basic Medical, Southern Medical University, Guangzhou 510515, China.
Yihan ZhuDepartment of Biochemistry and Molecular Biology, School of Basic Medical, Southern Medical University, Guangzhou 510515, China.
Xiaolei WeiDepartment of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Yu HuDivision of Nephrology, Nanfang Hospital, Southern Medical University, State Key Laboratory of Multi-organ Injury Prevention and Treatment, National Clinical Research Center for Kidney Disease, Guangdong Provincial Institute of Nephrology, Guangdong Provincial Key Laboratory of Renal Failure Research, Guangzhou, Guangdong 510515, China.
Enguang BiDepartment of Biochemistry and Molecular Biology, School of Basic Medical, Southern Medical University, Guangzhou 510515, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple myeloma (MM) remains an incurable malignancy characterized by the proliferation of malignant plasma cells and significant dysregulation within the bone marrow microenvironment. Plasmacytoid dendritic cells (pDCs) play a crucial role in the immune landscape of MM, often being co-opted by MM cells to support tumor progression. In this study, we identified

Indexed as

drug therapyMT: Regular Issuemultiple myelomaplasmacytoid dendritic cellretinoic acidtype I interferon

Identifiers

PMID40502919
PMCPMC12158611

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.